Alzheimer's Disease (AD) emerges as one of the more prevalent chronic neurodegenerative disorders relating to aging. It progressively weakens a person’s mental capabilities and functioning. Currently, over 55 million people smart from this disease crosswise the globe. Additionally, recent projections approximation a staggering rise to 152 million by the year 2050. This underscores the critical need for early diagnosis. Detecting early-stage Alzheimer’s Disease is now being accomplished by conventional Artificial Intelligence methods such as Machine Learning and Deep Learning Techniques. They outperform prior methods. From neuroimaging alone, AI Systems were able to effectively diagnose Alzheimer’s patients with 96% accuracy along with predictive model statements utilizing cognitive assessment data and other biomarkers. For instance, AI models flawlessly predicted 94% of neuroimaging data while AI cognitive tests diagnosed early AD in 91% of cases. Moreover, AI blood biomarker analyses reached 93% accuracy, and AI retinal scans identified early AD signs with 92% accuracy. This type of innovation enables preclinical Alzheimer’s detection, presenting opportunities for timely intervention and improved control of the disease. Despite these promising developments, issues like standardization of data, privacy, and model interpretability remain. On the other hand, the AD diagnostic AI applications inevitability hope worsens faster than fulfills. Advanced AD care could result from earlier and more precise identification, enhanced patient results, and tailored approaches to treatment and proactive measures adopting further research and development AI technologies in the battle against Alzheimer's Disease.
A Fri, study studied this question.